These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 21747030)

  • 1. In vivo assessment of vesicular monoamine transporter type 2 in dementia with lewy bodies and Alzheimer disease.
    Villemagne VL; Okamura N; Pejoska S; Drago J; Mulligan RS; Chételat G; Ackermann U; O'Keefe G; Jones G; Gong S; Tochon-Danguy H; Kung HF; Masters CL; Skovronsky DM; Rowe CC
    Arch Neurol; 2011 Jul; 68(7):905-12. PubMed ID: 21747030
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential diagnosis in Alzheimer's disease and dementia with Lewy bodies via VMAT2 and amyloid imaging.
    Villemagne VL; Okamura N; Pejoska S; Drago J; Mulligan RS; Chételat G; O'Keefe G; Jones G; Kung HF; Pontecorvo M; Masters CL; Skovronsky DM; Rowe CC
    Neurodegener Dis; 2012; 10(1-4):161-5. PubMed ID: 22261520
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differentiating Alzheimer's disease from dementia with Lewy bodies and Parkinson's disease with (+)-[11C]dihydrotetrabenazine positron emission tomography.
    Koeppe RA; Gilman S; Junck L; Wernette K; Frey KA
    Alzheimers Dement; 2008 Jan; 4(1 Suppl 1):S67-76. PubMed ID: 18632004
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vivo measurement of vesicular monoamine transporter type 2 density in Parkinson disease with (18)F-AV-133.
    Okamura N; Villemagne VL; Drago J; Pejoska S; Dhamija RK; Mulligan RS; Ellis JR; Ackermann U; O'Keefe G; Jones G; Kung HF; Pontecorvo MJ; Skovronsky D; Rowe CC
    J Nucl Med; 2010 Feb; 51(2):223-8. PubMed ID: 20080893
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PET imaging of amyloid with Florbetapir F 18 and PET imaging of dopamine degeneration with 18F-AV-133 (florbenazine) in patients with Alzheimer's disease and Lewy body disorders.
    Siderowf A; Pontecorvo MJ; Shill HA; Mintun MA; Arora A; Joshi AD; Lu M; Adler CH; Galasko D; Liebsack C; Skovronsky DM; Sabbagh MN
    BMC Neurol; 2014 Apr; 14():79. PubMed ID: 24716655
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinicopathological Correlation: Dopamine and Amyloid PET Imaging with Neuropathology in Three Subjects Clinically Diagnosed with Alzheimer's Disease or Dementia with Lewy Bodies.
    Gupta HV; Beach TG; Mehta SH; Shill HA; Driver-Dunckley E; Sabbagh MN; Belden CM; Liebsack C; Dugger BN; Serrano GE; Sue LI; Siderowf A; Pontecorvo MJ; Mintun MA; Joshi AD; Adler CH
    J Alzheimers Dis; 2021; 80(4):1603-1612. PubMed ID: 33720879
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Striatal monoamine terminals in Lewy body dementia and Alzheimer's disease.
    Gilman S; Koeppe RA; Little R; An H; Junck L; Giordani B; Persad C; Heumann M; Wernette K
    Ann Neurol; 2004 Jun; 55(6):774-80. PubMed ID: 15174011
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vivo detection of monoaminergic degeneration in early Parkinson disease by (18)F-9-fluoropropyl-(+)-dihydrotetrabenzazine PET.
    Lin SC; Lin KJ; Hsiao IT; Hsieh CJ; Lin WY; Lu CS; Wey SP; Yen TC; Kung MP; Weng YH
    J Nucl Med; 2014 Jan; 55(1):73-9. PubMed ID: 24287322
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimal scanning time window for 18F-FP-(+)-DTBZ (18F-AV-133) summed uptake measurements.
    Lin KJ; Lin WY; Hsieh CJ; Weng YH; Wey SP; Lu CS; Skovronsky D; Yen TC; Chang CJ; Kung MP; Hsiao IT
    Nucl Med Biol; 2011 Nov; 38(8):1149-55. PubMed ID: 21831650
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of 99mTc-TRODAT-1 SPECT and 18 F-AV-133 PET imaging in healthy controls and Parkinson's disease patients.
    Hsiao IT; Weng YH; Lin WY; Hsieh CJ; Wey SP; Yen TC; Kung MP; Lu CS; Lin KJ
    Nucl Med Biol; 2014 Apr; 41(4):322-9. PubMed ID: 24503330
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Distinguishing between dementia with Lewy bodies and Alzheimer's disease using metabolic patterns.
    Ye BS; Lee S; Yoo H; Chung SJ; Lee YH; Choi Y; Lee PH; Sohn YH; Yun M
    Neurobiol Aging; 2020 Mar; 87():11-17. PubMed ID: 31791660
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differentiation of dementia with Lewy bodies from Alzheimer's disease using a dopaminergic presynaptic ligand.
    Walker Z; Costa DC; Walker RW; Shaw K; Gacinovic S; Stevens T; Livingston G; Ince P; McKeith IG; Katona CL
    J Neurol Neurosurg Psychiatry; 2002 Aug; 73(2):134-40. PubMed ID: 12122169
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dementia with Lewy bodies versus Alzheimer's disease: role of dopamine transporter imaging.
    Costa DC; Walker Z; Walker RW; Fontes FR
    Mov Disord; 2003 Oct; 18 Suppl 7():S34-8. PubMed ID: 14531044
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dopamine transporter loss visualized with FP-CIT SPECT in the differential diagnosis of dementia with Lewy bodies.
    O'Brien JT; Colloby S; Fenwick J; Williams ED; Firbank M; Burn D; Aarsland D; McKeith IG
    Arch Neurol; 2004 Jun; 61(6):919-25. PubMed ID: 15210531
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The application of statistical parametric mapping to 123I-FP-CIT SPECT in dementia with Lewy bodies, Alzheimer's disease and Parkinson's disease.
    Colloby SJ; O'Brien JT; Fenwick JD; Firbank MJ; Burn DJ; McKeith IG; Williams ED
    Neuroimage; 2004 Nov; 23(3):956-66. PubMed ID: 15528096
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The 18F-FDG PET cingulate island sign and comparison to 123I-beta-CIT SPECT for diagnosis of dementia with Lewy bodies.
    Lim SM; Katsifis A; Villemagne VL; Best R; Jones G; Saling M; Bradshaw J; Merory J; Woodward M; Hopwood M; Rowe CC
    J Nucl Med; 2009 Oct; 50(10):1638-45. PubMed ID: 19759102
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dementia with Lewy bodies can be well-differentiated from Alzheimer's disease by measurement of brain acetylcholinesterase activity-a [11C]MP4A PET study.
    Shimada H; Hirano S; Sinotoh H; Ota T; Tanaka N; Sato K; Yamada M; Fukushi K; Irie T; Zhang MR; Higuchi M; Kuwabara S; Suhara T
    Int J Geriatr Psychiatry; 2015 Nov; 30(11):1105-13. PubMed ID: 26280153
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quantitative analysis of binding sites for 9-fluoropropyl-(+)-dihydrotetrabenazine ([¹⁸F]AV-133) in a MPTP-lesioned PD mouse model.
    Chao KT; Tsao HH; Weng YH; Hsiao IT; Hsieh CJ; Wey SP; Yen TC; Kung MP; Lin KJ
    Synapse; 2012 Sep; 66(9):823-31. PubMed ID: 22623146
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Decreased striatal monoaminergic terminals in Huntington disease.
    Bohnen NI; Koeppe RA; Meyer P; Ficaro E; Wernette K; Kilbourn MR; Kuhl DE; Frey KA; Albin RL
    Neurology; 2000 May; 54(9):1753-9. PubMed ID: 10802780
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fluoroalkyl derivatives of dihydrotetrabenazine as positron emission tomography imaging agents targeting vesicular monoamine transporters.
    Goswami R; Ponde DE; Kung MP; Hou C; Kilbourn MR; Kung HF
    Nucl Med Biol; 2006 Aug; 33(6):685-94. PubMed ID: 16934687
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.